BIOGEN INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOGEN INC, and what generic alternatives to BIOGEN INC drugs are available?
BIOGEN INC has three approved drugs.
There are seventeen US patents protecting BIOGEN INC drugs.
There are two hundred and twenty-one patent family members on BIOGEN INC drugs in forty-two countries and forty-seven supplementary protection certificates in thirteen countries.
Summary for BIOGEN INC
| International Patents: | 221 |
| US Patents: | 17 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for BIOGEN INC: | See patent lawsuits for BIOGEN INC |
| PTAB Cases with BIOGEN INC as patent owner: | See PTAB cases with BIOGEN INC as patent owner |
Drugs and US Patents for BIOGEN INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 10,391,160 | ⤷ Subscribe | ⤷ Subscribe | |||
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 11,246,850 | ⤷ Subscribe | ⤷ Subscribe | |||
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | AB | RX | Yes | No | 11,007,166 | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BIOGEN INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 8,524,773 | ⤷ Subscribe |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 6,509,376 | ⤷ Subscribe |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 7,803,840 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BIOGEN INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-releaseCapsules | 120 mg and 240 mg | ➤ Subscribe | 2017-03-27 |
International Patents for BIOGEN INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2019001807 | ⤷ Subscribe |
| China | 115974955 | ⤷ Subscribe |
| Singapore | 10201802389S | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BIOGEN INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0605697 | SPC/GB01/008 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 |
| 2970101 | PA2022003,C2970101 | Lithuania | ⤷ Subscribe | PRODUCT NAME: DIROKSIMELIO FUMARATAS ; REGISTRATION NO/DATE: EU/1/21/1585 20211115 |
| 1131065 | 1490039-3 | Sweden | ⤷ Subscribe | PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
